H. Suttmann

5.1k total citations
49 papers, 1.6k citations indexed

About

H. Suttmann is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, H. Suttmann has authored 49 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 14 papers in Surgery and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in H. Suttmann's work include Prostate Cancer Treatment and Research (17 papers), Bladder and Urothelial Cancer Treatments (11 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). H. Suttmann is often cited by papers focused on Prostate Cancer Treatment and Research (17 papers), Bladder and Urothelial Cancer Treatments (11 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). H. Suttmann collaborates with scholars based in Germany, United States and United Kingdom. H. Suttmann's co-authors include Sven Brandau, Michael Stöckle, Jan Lehmann, Andreas Böhle, D. Jocham, Gerhard Unteregger, Friedrich Paulsen, Margitta Retz, Jürgen Harder and Jörn Kamradt and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

H. Suttmann

45 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Suttmann Germany 16 633 429 408 289 286 49 1.6k
Hetal Patel United Kingdom 19 644 1.0× 217 0.5× 488 1.2× 120 0.4× 315 1.1× 47 1.7k
Sonya Abraham United Kingdom 15 599 0.9× 103 0.2× 484 1.2× 263 0.9× 77 0.3× 44 1.5k
James B. Breitmeyer United States 23 653 1.0× 277 0.6× 609 1.5× 412 1.4× 107 0.4× 60 2.1k
Robert Paquin Canada 16 474 0.7× 110 0.3× 217 0.5× 123 0.4× 140 0.5× 26 982
Joanna Murray United Kingdom 20 441 0.7× 335 0.8× 308 0.8× 75 0.3× 150 0.5× 31 1.1k
Larry L. Thomas United States 25 885 1.4× 305 0.7× 693 1.7× 97 0.3× 292 1.0× 55 2.3k
Einar E. Eriksson Sweden 22 1.1k 1.7× 177 0.4× 535 1.3× 186 0.6× 138 0.5× 39 2.1k
Kamal A. Mohammed United States 27 299 0.5× 249 0.6× 508 1.2× 234 0.8× 793 2.8× 58 1.7k
Zhi-Hua Cui China 16 760 1.2× 76 0.2× 361 0.9× 206 0.7× 134 0.5× 41 1.6k
Hajime Ishinaga Japan 18 192 0.3× 175 0.4× 298 0.7× 103 0.4× 162 0.6× 75 1.0k

Countries citing papers authored by H. Suttmann

Since Specialization
Citations

This map shows the geographic impact of H. Suttmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Suttmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Suttmann more than expected).

Fields of papers citing papers by H. Suttmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Suttmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Suttmann. The network helps show where H. Suttmann may publish in the future.

Co-authorship network of co-authors of H. Suttmann

This figure shows the co-authorship network connecting the top 25 collaborators of H. Suttmann. A scholar is included among the top collaborators of H. Suttmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Suttmann. H. Suttmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chi, K.N., Andrew Protheroe, A. Rodrı́guez-Antolı́n, et al.. (2017). Benefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO). Annals of Oncology. 28. v269–v269. 6 indexed citations
2.
Miller, K., Peter Albers, Marc‐Oliver Grimm, et al.. (2016). Metastasiertes kastrationsresistentes Prostatakarzinom. Der Urologe. 55(9). 1206–1212.
3.
Miller, K., Peter Albers, Marc‐Oliver Grimm, et al.. (2014). Metastasiertes kastrationsresistentes Prostatakarzinom. Der Urologe. 53(5). 710–714. 3 indexed citations
4.
5.
Goodman, Oscar B., Thomas W. Flaig, A. Molina, et al.. (2013). Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 17(1). 34–39. 79 indexed citations
6.
Merseburger, Axel S., H. Suttmann, David Schilling, et al.. (2011). Novel options for the treatment of castration-resistant prostate cancer. World Journal of Urology. 30(4). 495–503. 13 indexed citations
7.
Saar, Matthias, Christina Körbel, Volker Jung, et al.. (2010). Experimental orthotopic prostate tumor in nude mice: Techniques for local cell inoculation and three-dimensional ultrasound monitoring. Urologic Oncology Seminars and Original Investigations. 30(3). 330–338. 11 indexed citations
8.
Suttmann, H., Aleksandar Grgic, Jan Lehmann, et al.. (2008). Combining 153 Sm-Lexidronam and Docetaxel for the Treatment of Patients with Hormone-Refractory Prostate Cancer: First Experience. Cancer Biotherapy and Radiopharmaceuticals. 23(5). 609–618. 15 indexed citations
9.
Suttmann, H., Margitta Retz, Friedrich Paulsen, et al.. (2008). Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells. BMC Urology. 8(1). 5–5. 146 indexed citations
10.
Mottrie, Alexandre, P. Carpentier, Peter Schatteman, et al.. (2007). Robot-assisted laparoscopic radical cystectomy: initial experience on 27 consecutive patients. Journal of Robotic Surgery. 1(3). 197–201. 11 indexed citations
11.
Suttmann, H., Jörn Kamradt, Jan Lehmann, & Michael Stöckle. (2007). Improving the prognosis of patients after radical cystectomy. Part I: the role of lymph node dissection. British Journal of Urology. 100(6). 1221–1224. 16 indexed citations
12.
Lehmann, Jan, H. Suttmann, Markus Hack, et al.. (2006). Transitional Cell Carcinoma of the Ureter: Prognostic Factors Influencing Progression and Survival. European Urology. 51(5). 1281–1288. 67 indexed citations
13.
Lehmann, Jan, Margitta Retz, Sukhvinder Sidhu, et al.. (2006). Antitumor Activity of the Antimicrobial Peptide Magainin II against Bladder Cancer Cell Lines. European Urology. 50(1). 141–147. 180 indexed citations
14.
Böhle, Andreas, H. Suttmann, & Sven Brandau. (2006). Wirkmechanismen der intravesikalen BCG-Immuntherapie des oberflächlichen Harnblasenkarzinoms. Der Urologe. 45(5). 629–636. 2 indexed citations
15.
Becker, Frank, H. Suttmann, Stefan Siemer, & Michael Stöckle. (2006). Is there a place for surveillance in the management of small renal tumors?. Nature Clinical Practice Urology. 3(12). 626–627. 3 indexed citations
16.
Suttmann, H., D. Jocham, Andreas Böhle, & Sven Brandau. (2002). The role of LFA-1 in the lysis of bladder cancer cells by bacillus Calmette-Guérin and interleukin 2-activated killer cells. Urological Research. 30(4). 233–239. 5 indexed citations
17.
Brandau, Sven, H. Suttmann, Hans‐Dieter Flad, D. Jocham, & Andreas Böhle. (2000). Killing of Fas ligand-resistant renal carcinoma cells by interleukin-2- and BCG-activated effector cells. Cancer Immunology Immunotherapy. 49(7). 369–376. 5 indexed citations
18.
Brandau, Sven, H. Suttmann, Ulrike Seitzer, et al.. (2000). Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.. PubMed. 6(9). 3729–38. 39 indexed citations
19.
Suttmann, H., et al.. (1988). [Patient-controlled analgesia. A technical toy or a contribution to the treatment of pain?].. PubMed. 37(8). 543–50. 4 indexed citations
20.
Doenicke, Α., et al.. (1984). [The action of the benzodiazepine antagonist Ro 15-1788].. PubMed. 33(8). 343–7. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hetal Patel Breakdown of academic impact, for papers by Sonya Abraham Breakdown of academic impact, for papers by James B. Breitmeyer Breakdown of academic impact, for papers by Robert Paquin Breakdown of academic impact, for papers by Joanna Murray Breakdown of academic impact, for papers by Larry L. Thomas Breakdown of academic impact, for papers by Einar E. Eriksson Breakdown of academic impact, for papers by Kamal A. Mohammed Breakdown of academic impact, for papers by Zhi-Hua Cui Breakdown of academic impact, for papers by Hajime Ishinaga
Rankless by CCL
2026